Eversept Partners’s Biogen BIIB Stock Holding History

Eversept Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50,000	Closed	-$13.3M	–	71
2022 Q3	$13.3M	Buy	+50,000	New	+$10.6M	1.16%	20
2021 Q3	–	Sell	-2,000	Closed	-$693K	–	109
2021 Q2	$693K	Buy	+2,000	New	+$606K	0.05%	85

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Eversept Partners's BIIB Position: Q1 2026 in Review

Eversept Partners sold out of Biogen (BIIB) in Q1 2026, closing a stake of 77,944 shares — an estimated $13.7M sold.

Eversept Partners first reported a position in BIIB in Q4 2021 and held it in 8 quarters. The position peaked at $42.8M in Q1 2023. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Eversept Partners reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
Eversept Partners sold 77,944 Biogen shares in Q1 2026, an estimated $13.7M.
Eversept Partners first reported a position in Biogen in Q4 2021 and held it in 8 quarters.
Eversept Partners's Biogen position peaked at $42.8M in Q1 2023.
1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.